Anika Therapeutics, Inc. (ANIK)
20.86
-0.13
(-0.62%)
USD |
NASDAQ |
Sep 11, 16:00
20.83
-0.03
(-0.14%)
After-Hours: 20:00
Anika Therapeutics Enterprise Value : 266.01M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 266.01M |
| September 10, 2026 | 267.75M |
| September 09, 2026 | 266.28M |
| September 08, 2026 | 268.42M |
| September 04, 2026 | 265.34M |
| September 03, 2026 | 267.88M |
| September 02, 2026 | 275.24M |
| September 01, 2026 | 269.35M |
| August 31, 2026 | 266.14M |
| August 28, 2026 | 269.22M |
| August 27, 2026 | 265.74M |
| August 26, 2026 | 276.98M |
| August 25, 2026 | 273.23M |
| August 24, 2026 | 272.43M |
| August 21, 2026 | 278.32M |
| August 20, 2026 | 272.43M |
| August 19, 2026 | 271.36M |
| August 18, 2026 | 275.51M |
| August 17, 2026 | 274.17M |
| August 14, 2026 | 274.57M |
| August 13, 2026 | 270.16M |
| August 12, 2026 | 281.67M |
| August 11, 2026 | 270.96M |
| August 10, 2026 | 263.60M |
| August 07, 2026 | 273.50M |
| Date | Value |
|---|---|
| August 06, 2026 | 256.64M |
| August 05, 2026 | 243.66M |
| August 04, 2026 | 249.28M |
| August 03, 2026 | 264.33M |
| July 31, 2026 | 244.86M |
| July 30, 2026 | 228.67M |
| July 29, 2026 | 203.24M |
| July 28, 2026 | 189.59M |
| July 27, 2026 | 187.85M |
| July 24, 2026 | 186.91M |
| July 23, 2026 | 183.17M |
| July 22, 2026 | 187.72M |
| July 21, 2026 | 189.72M |
| July 20, 2026 | 188.39M |
| July 17, 2026 | 190.93M |
| July 16, 2026 | 198.56M |
| July 15, 2026 | 200.03M |
| July 14, 2026 | 194.54M |
| July 13, 2026 | 197.89M |
| July 10, 2026 | 195.61M |
| July 09, 2026 | 202.17M |
| July 08, 2026 | 205.52M |
| July 07, 2026 | 199.23M |
| July 06, 2026 | 201.37M |
| July 02, 2026 | 192.40M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 87.67M |
| MiMedx Group, Inc. | 547.33M |
| ABVC BioPharma, Inc. | 30.03M |
| Intuitive Surgical, Inc. | 125.52B |
| Enovis Corp. | 2.470B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.309M |
| Revenue (Quarterly) | 32.61M |
| Total Expenses (Quarterly) | 29.30M |
| EPS Diluted (Quarterly) | 0.2412 |
| Gross Profit Margin (Quarterly) | 65.15% |
| Profit Margin (Quarterly) | 10.15% |
| Earnings Yield | -1.31% |
| Normalized Earnings Yield | -1.314 |